These studies yielded inconsistent results and produced side effects that might be due to the short half-life of recombinant VEGF in plasma, genomic integration, an immune response against the vector, a limitation of controlled release, and off-target side effects associated with systemic delivery, development of edema or angioma due to AAV-based prolonged expression of VEGF. This evidence concerns the gene VEGFA and hemangioma.